- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05237128
The Lifestyle Education About Nutrition for Diabetes (Legend) Study (LEGEND)
Comparing Two Dietary Approaches for Type 2 Diabetes: The LEGEND (Lifestyle Education About Nutrition for Diabetes) Study
This study is being completed to compare two dietary approaches for participants with type 2 diabetes. This research will test whether a very low-carbohydrate or a plate-method diet better improves outcomes for blood glucose control and body composition for patients with type 2 diabetes that follow one of these approaches for 12 months.
Participants that meet screening and eligibility will be randomized to one of the two diets. In addition to the diet, study specific visits and assessments will be performed at various timepoints.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- The University of California San Francisco (UCSF)
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- diagnosis of type 2 diabetes, with current HbA1c > 6.5% and < 12% (self-reported and then measured at screening)
- ability to speak English (this is a group-based intervention)
- ability to engage in light physical activity
- willingness to be randomized to either type of diet
Exclusion Criteria:
- unable to provide informed consent
- substance abuse, mental health, cognitive, or medical condition that would, in the opinion of the investigators, make it difficult for the individual to take part in the intervention, may alter key outcomes, or may require important diet modifications and includes conditions such as hypercalcemia or thyroid dysfunction
- pregnant or planning to become pregnant in the next 12 months, or currently breastfeeding (pregnancy and breastfeeding require modifications to the intervention's dietary approaches)
- current use of weight loss medications (this is likely to alter weight outcomes and may alter other measures)
- history of weight loss (bariatric) surgery or plans for bariatric surgery in the next year
- currently enrolled in a weight loss program or have unalterable plans to enroll in one of these programs in the next year
- vegan or vegetarian
- unwilling or unable to participate in study measurements and group classes
- current use of systemic steroids (self-reported in screening survey; oral or IV systemic steroids excluded. Injected steroids may be permitted depending on frequency and timing of injections with regard to lab assessments (minimum of 2 weeks between injection and blood tests))
- weight above 400 pounds (weight limit for dual-energy X-ray absorptiometry (DEXA) scans)
- history of multiple or recent (within the last four years) kidney stones
- currently following a very low-carbohydrate diet
- unwilling to stop an SGLT2 inhibitor medication if the participant were to be randomized to the very low-carbohydrate diet
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Very low-carbohydrate diet
|
Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or "keto" diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc. There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month. |
|
Experimental: Moderate-carbohydrate plate-method diet
|
Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats. There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HbA1c
Time Frame: 0 to 12 months
|
HbA1c will be measured by standard immunoturbidimetric assay methods and quality control measures at a Clinical Laboratory Improvement Amendments (CLIA) certified lab.
|
0 to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in percent body fat on DEXA
Time Frame: 0 to 12 months
|
This will be measured by dual-energy X-ray absorptiometry scan
|
0 to 12 months
|
|
Change in small particle low-density lipoproteins (LDL)
Time Frame: 0 to 12 months
|
0 to 12 months
|
|
|
Change in high-density lipoproteins (HDL)
Time Frame: 0 to 12 months
|
0 to 12 months
|
|
|
Change in triglycerides
Time Frame: 0 to 12 months
|
0 to 12 months
|
|
|
Change in Inflammation based on high sensitivity C-reactive protein (hsCRP)
Time Frame: 0 to 12 months
|
High-sensitivity C-reactive protein will be measured with nephelometric methods utilizing latex particles coated with CRP monoclonal antibodies and standardized against a CRP reference preparation.
|
0 to 12 months
|
|
Change in percent body weight loss
Time Frame: 0 to 12 months
|
0 to 12 months
|
|
|
Change in percent lean body mass on DEXA
Time Frame: 0 to 12 months
|
This will be measured by dual-energy X-ray absorptiometry scan
|
0 to 12 months
|
|
Change in bone mineral density in total hip
Time Frame: 0 to 12 months
|
This will be measured by dual-energy X-ray absorptiometry scan
|
0 to 12 months
|
|
Change in bone mineral density in lumbar spine
Time Frame: 0 to 12 months
|
This will be measured by dual-energy X-ray absorptiometry scan
|
0 to 12 months
|
|
Change in serum procollagen type I N propeptide (s-PINP)
Time Frame: 0 to 12 months
|
0 to 12 months
|
|
|
Change in serum c-terminal telopeptide of type 1 collagen (s-CTX)
Time Frame: 0 to 12 months
|
0 to 12 months
|
|
|
Reduction in diabetes medications using medication effect score (MES)
Time Frame: 0 to 12 months
|
The medication effect score is a means of assessing the overall intensity of a patient's diabetes pharmacotherapy based on potency and dosages of medications (Alexopoulos et al., 2021).
|
0 to 12 months
|
|
Change in HbA1c
Time Frame: 0 to 4 months
|
HbA1c will be measured by standard immunoturbidimetric assay methods and quality control measures at a Clinical Laboratory Improvement Amendments (CLIA) certified lab.
|
0 to 4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Saslow, PhD, University of Michigan
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00202808
- R01DK126898-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsNot yet recruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
University of PennsylvaniaNational Institute on Aging (NIA); American Heart AssociationRecruitingType 2 Diabetes Mellitus | Type 2 Diabetes | Type II Diabetes Mellitus | Pre-diabetes | Pre-diabetic | Type II Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2DM) | Pre-diabetic StateUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
Clinical Trials on Very low-carbohydrate diet
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 1 DiabetesUnited States
-
University of North Carolina, Chapel HillCompletedDiarrhea Predominant Irritable Bowel SyndromeUnited States
-
Dr. Soetomo General HospitalUnknownDiet Modification | Colorectal Adenocarcinoma | Systemic Inflammation | Lactate | TNF Alpha
-
Boston Children's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Brigham...Completed
-
Touro University, CaliforniaCompletedCholesterol Metabolism | Ketone MetabolismUnited States
-
National Center for Complementary and Integrative...Community Foundation of Southeastern MichiganCompleted
-
Nemours Children's ClinicCompletedDiet Modification | Type 1 Diabetes Mellitus | Child, OnlyUnited States
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
CAMC Health SystemCompletedInsulin Resistance | Abdominal Obesity | Systolic Hypertension | Elevated TriglyceridesUnited States
-
Boston Children's HospitalRecruitingType1diabetesUnited States